Literature DB >> 28266709

Bone loss in C57BL/6J-OlaHsd mice, a substrain of C57BL/6J carrying mutated alpha-synuclein and multimerin-1 genes.

Tamar Liron1, Bitya Raphael1, Sahar Hiram-Bab1, Itai A Bab2, Yankel Gabet1.   

Abstract

The inbred mouse strain C57BL/6 is commonly used for the generation of transgenic mouse and is a well established strain in bone research. Different vendors supply different substrains of C57BL/6J as wild-type animals when genetic drift did not incur any noticeable phenotype. However, we sporadically observed drastic differences in the bone phenotype of "WT" C57BL/6J mice originating from different labs and speculated that these variations are attributable, at least in part, to the variation between C57BL/6J substrains, which is often overlooked. C57BL/6J-OlaHsd is a commonly used substrain that despite a well defined deletion in the alpha-synuclein (Snca) and multimerin-1 (Mmrn1) genes, was reported to display no obvious phenotype and is used as WT control. Here, we compared the bone phenotype of C57BL/6J-OlaHsd (6J-OLA) to C57BL/6J-RccHsd (6J-RCC) and to the original C57BL/6J (6J-JAX). Using μCT analysis, we found that 6J-OLA mice display a significantly lower trabecular bone mass compared to 6J-RCC and 6J-JAX. PCR analysis revealed that both the Snca and Mmrn1 genes are expressed in bone tissue of 6J-RCC animals but not of 6J-OLA mutants, suggesting either one or both genes play a role in bone metabolism. In vitro analysis demonstrated increase in osteoclasts number and decreased osteoblast mineralization in cells derived from 6J-OLA compared with 6J-RCC. Our data may shed light on unexplained differences in basal bone measurements between different research centers and reiterate the importance of specifying the exact substrain type. In addition, our findings describe the physiological role for Mmrn1 and/or Snca in bone remodeling.
© 2017 Wiley Periodicals, Inc.

Entities:  

Keywords:  C57Bl/6J substrains; bone mass accrual; genetic drift; osteoporosis; peak bone mass

Mesh:

Substances:

Year:  2017        PMID: 28266709     DOI: 10.1002/jcp.25895

Source DB:  PubMed          Journal:  J Cell Physiol        ISSN: 0021-9541            Impact factor:   6.384


  8 in total

Review 1.  Genomic evolution of cancer models: perils and opportunities.

Authors:  Uri Ben-David; Rameen Beroukhim; Todd R Golub
Journal:  Nat Rev Cancer       Date:  2019-02       Impact factor: 60.716

2.  S-allylmercapto-N-acetylcysteine protects bone cells from oxidation and improves femur microarchitecture in healthy and diabetic mice.

Authors:  Reem Abu-Kheit; Shlomo Kotev-Emeth; Sahar Hiram-Bab; Yankel Gabet; Naphtali Savion
Journal:  Exp Biol Med (Maywood)       Date:  2022-06-06

Review 3.  Research-Relevant Conditions and Pathology of Laboratory Mice, Rats, Gerbils, Guinea Pigs, Hamsters, Naked Mole Rats, and Rabbits.

Authors:  Timothy K Cooper; David K Meyerholz; Amanda P Beck; Martha A Delaney; Alessandra Piersigilli; Teresa L Southard; Cory F Brayton
Journal:  ILAR J       Date:  2021-12-31       Impact factor: 1.521

Review 4.  The impact of genetic background on mouse models of kidney disease.

Authors:  Rei Bufi; Ron Korstanje
Journal:  Kidney Int       Date:  2022-04-13       Impact factor: 18.998

5.  Deletion in chromosome 6 spanning alpha-synuclein and multimerin1 loci in the Rab27a/b double knockout mouse.

Authors:  Rudradip Pattanayak; Rachel Underwood; Michael R Crowley; David K Crossman; Jennifer R Morgan; Talene A Yacoubian
Journal:  Sci Rep       Date:  2022-06-14       Impact factor: 4.996

6.  Substrains matter in phenotyping of C57BL/6 mice.

Authors:  Kazuyuki Mekada; Atsushi Yoshiki
Journal:  Exp Anim       Date:  2021-01-14

Review 7.  Immune Relevant and Immune Deficient Mice: Options and Opportunities in Translational Research.

Authors:  Enrico Radaelli; Sara F Santagostino; Rani S Sellers; Cory F Brayton
Journal:  ILAR J       Date:  2018-12-31

Review 8.  Multimerin-1 and cancer: a review.

Authors:  Mareike G Posner
Journal:  Biosci Rep       Date:  2022-02-25       Impact factor: 3.840

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.